599 results on '"Rosenblat, Joshua D"'
Search Results
2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
3. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
4. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression
5. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine
6. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
7. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
8. Comparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis
9. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
10. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
11. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
12. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
13. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
14. Association between cognitive functioning, suicidal ideation and suicide attempts in major depressive disorder, bipolar disorder, schizophrenia and related disorders: A systematic review and meta-analysis
15. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists
16. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review
17. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
18. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
19. Depression, anxiety and post-traumatic stress during the 2022 Russo-Ukrainian war, a comparison between populations in Poland, Ukraine, and Taiwan
20. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
21. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
22. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review
23. Peripheral inflammatory biomarkers define biotypes of bipolar depression
24. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
25. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
26. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
27. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis
28. Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders
29. A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
30. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
31. Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD
32. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity
33. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
34. Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
35. Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review
36. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
37. Ketamine use in pediatric depression: A systematic review
38. Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis
39. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
40. The abuse liability of ketamine: A scoping review of preclinical and clinical studies
41. Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
42. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
43. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis
44. Pharmacogenomics of ketamine: A systematic review
45. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence
46. Prescribed psychostimulants and other pro‐cognitive medications in bipolar disorder: A systematic review and meta‐analysis of recurrence of manic symptoms.
47. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis.
48. Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review
49. Onset and frequency of depression in post-COVID-19 syndrome: A systematic review
50. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.